The number needed to treat with dupilumab to prevent moderate or severe chronic obstructive pulmonary disease exacerbations: BOREAS and NOTUS - Amsterdam 2025

Biologics for COPD: cutting-edge data

Chair(s): Alexander Mathioudakis, Maeva Zysman

Session type: Poster session

The number needed to treat with dupilumab to prevent moderate or severe chronic obstructive pulmonary disease exacerbations: BOREAS and NOTUS

Nicola Hanania

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Reduction of NIV utilization in patients with COPD treated for type II inflammation with biologics

Truong-an Ho

Poster

Abstract

Dupilumab efficacy in patients with chronic obstructive pulmonary disease and cardiovascular or metabolic disease: BOREAS and NOTUS

John R Hurst

Poster

Abstract

Late Breaking Abstract - A phase 2 study of a new humanized anti-IL-4R? mAb (SSGJ-611) in COPD

Dandan Chen

Poster

Abstract

Biologics for COPD: How many patients will be eligible?

Michael Clarkson

Poster

Abstract

DUPILUMAB AS A TREATMENT IN PATIENTS WITH GOLD-E EOSINOPHILIC COPD: EXPERIENCE IN A SECOND-LEVEL HOSPITAL

Cesar Alejandro Araque Molina

Poster

Abstract

Efficacy of mepolizumab in patients with COPD & type 2 inflammation: Pooled Phase III trial results

Claus Vogelmeier

Poster

Abstract

Effect of add-on dupilumab in elderly patients with chronic obstructive pulmonary disease: BOREAS and NOTUS

David Mannino

Poster

Abstract

The number needed to treat with dupilumab to prevent moderate or severe chronic obstructive pulmonary disease exacerbations: BOREAS and NOTUS

Nicola Hanania

Poster

Abstract

Association between dupilumab and repeated exacerbations of chronic obstructive pulmonary disease: BOREAS and NOTUS

Mona Bafadhel

Poster

Abstract

A Phase 1 Study of the IRAK4 inhibitor, AZD6793, evaluating Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Patients with COPD

Caroline Owen

Poster

Abstract

A potent anti-TSLP mAb reduces type 2 inflammation in primary COPD epithelial cells

Yoko Yasuda

Poster

Abstract

EFFECTIVENESS OF TREATMENT WITH MEPOLIZUMAB AND DUPILUMAB IN PATIENTS WITH ASTHMA-COPD OVERLAP (ACO) COMPARED TO PATIENTS WITH SEVERE UNCONTROLLED ASTHMA (SUA) WITHOUT COPD.

David Echavarria

Poster

Abstract

Relationship between improvement in lung function and patient-reported outcomes in chronic obstructive pulmonary disease with dupilumab treatment: causal mediation analyses

Surya Bhatt

Poster

Abstract

Win ratio analysis of dupilumab efficacy in patients with chronic obstructive pulmonary disease and type 2 inflammation: BOREAS and NOTUS

Sanjay Ramakrishnan

Poster

Abstract

COPD patients managed in primary care Proportion of patients potentially eligible for biologic therapy

Erik Sören Halvard Hansen

Poster

Abstract

Patient experiences during COPD care using biologics: a scoping review

Anastasiia Gorova

Poster

Abstract

Phagocytosis capacity in neutrophilic COPD patients.

James Baker

Poster

Abstract

Late Breaking Abstract - ZW1528: A dual-targeting bispecific antibody to broadly suppress airway inflammation by inhibiting IL-4Ra and IL-33 pathways

Blair Hardman

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}